Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis.
The coronaviruses mouse hepatitis virus type 2 (MHV-2) and severe acute respiratory syndrome coronavirus (SARS-CoV) utilize proteases to enter host cells. Upon receptor binding, the spike (S) proteins of both viruses are activated for membrane fusion by proteases, such as trypsin, present in the environment, facilitating virus entry from the cell surface. In contrast, in the absence of extracellular proteases, these viruses can enter cells via an endosomal pathway and utilize endosomal cathepsins for S protein activation. We demonstrate that the MHV-2 S protein uses multistep conformational changes for membrane fusion. After interaction with a soluble form of the MHV receptor (CEACAM1a), the metastable form of S protein is converted to a stable trimer, as revealed by mildly denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Liposome-binding assays indicate that the receptor-bound virions are associated with the target membrane through hydrophobic interactions. The exposure of receptor-bound S protein to trypsin or cathepsin L (CPL) induces the formation of six-helix bundles (6HB), the final conformation. This trypsin- or CPL-mediated conversion to 6HB can be blocked by a heptad repeat peptide known to block the formation of 6HB. Although trypsin treatment enabled receptor-bound MHV-2 to enter from the cell surface, CPL failed to do so. Interestingly, consecutive treatment with CPL and then chlorpromazine enabled a portion of the virus to enter from cell surface. These results suggest that trypsin suffices for the induction of membrane fusion of receptor-primed S protein, but an additional unidentified cellular factor is required to trigger membrane fusion by CPL.
Matsuyama
Shutoku
S
Department of Virology III, National Institute of Infectious Diseases, 4-7-1 Gakuen Musashi-Murayama, Tokyo 208-0011, Japan. matuyama@nih.go.jp
Taguchi
Fumihiro
F
D000818:Animals; D002272:Carcinoembryonic Antigen / Q000378:metabolism; D002403:Cathepsins / Q000378:metabolism; D008081:Liposomes / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D006517:Murine hepatitis virus / Q000378:metabolism*; D011485:Protein Binding; D011487:Protein Conformation; D064370:Spike Glycoprotein, Coronavirus; D014357:Trypsin / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D053586:Virus Internalization
D002272:Carcinoembryonic Antigen; C486183:Ceacam1 protein, mouse; D008081:Liposomes; D008562:Membrane Glycoproteins; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus; D002403:Cathepsins; D014357:Trypsin
J Virol. 2003 Jan;77(2):830-40
12502799
J Virol. 2004 Aug;78(15):8201-9
15254191
Mol Biol Cell. 1999 Jun;10(6):1821-36
10359599
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6
19321428
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81
16081529
J Virol. 2006 Apr;80(8):4174-8
16571833
Science. 2005 Jun 10;308(5728):1643-5
15831716
J Virol. 2009 Jan;83(2):712-21
18971274
Biochim Biophys Acta. 2009 Apr;1793(4):674-83
19014978
Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32
15040445
J Gen Virol. 2000 Dec;81(Pt 12):2867-2871
11086117
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12543-7
16116101
J Virol. 2002 Dec;76(23):11819-26
12414924
J Virol. 2008 Dec;82(23):11985-91
18786990
Structure. 2006 May;14(5):889-99
16698550
J Virol. 2006 Jun;80(12):5768-76
16731916
Crit Rev Biochem Mol Biol. 2008 May-Jun;43(3):189-219
18568847
J Virol. 1991 Jan;65(1):254-62
1985201
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5
15010527
J Gen Virol. 2005 Aug;86(Pt 8):2269-2274
16033974
J Biol Chem. 2002 May 31;277(22):19727-34
11912215
J Virol. 2004 Jan;78(1):216-23
14671103
Virology. 2006 Jan 5;344(1):25-9
16364732
J Virol. 2003 Aug;77(16):8801-11
12885899
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2580-5
9482929
J Virol. 2008 Sep;82(17):8887-90
18562523
J Virol. 2004 Oct;78(19):10328-35
15367599
Cell. 2000 Nov 10;103(4):679-89
11106737